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ABSTRACT
By analyzing the genomic data of head and neck squamous cell cancer (HNSCC), 
we investigated clinical significance of YAP1 activation. Copy number and mRNA 
expression of YAP1 were analyzed together to assess clinical relevance of YAP1 
activation in HNSCC. The clinical significance of YAP1 activation was further validated 
in four independent test cohorts. We also assessed the correlation of YAP1 activation 
with genomic alterations such as copy number alteration, somatic mutation, and 
miRNA expression. The YAP1-activated (YA) subgroup showed worse prognosis for 
HNSCC as tested and validated in five cohorts. In a multivariate risk analysis, the YAP1 
signature was the most significant predictor of overall survival. The YAP1-inactivated 
(YI) subgroup was associated with HPV-positive status. In multiplatform analysis, YA 
tumors had gain of EGFR and SNAI2; loss of tumor-suppressor genes such as CSMD1, 
CDKN2A, NOTCH1, and SMAD4; and high mutation rates of TP53 and CDKN2A. YI 
tumors were characterized by gain of PIK3CA, SOX2, and TP63; deletion of 11q23.1; 
and high mutation rates of NFE2L2, PTEN, SYNE1, and NSD1. YA tumors also showed 
weaker immune activity as reflected in low IFNG composite scores and YAP1 activity 
is negatively associated with potential response to treatment of pembrolizumab. In 
conclusion, activation of YAP1 is associated with worse prognosis of patients with 
HNSCC and potential resistance to immunotherapy.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth leading type of cancer worldwide, with an 
annual incidence of approximately 600,000 cases and a 
mortality rate of 40% to 50% [1, 2]. The major known 
risk factors are environmental exposures to tobacco 
products, alcohol, and infection with high-risk human 
papillomaviruses (HPV) [3]. Despite advances in our 
knowledge of the epidemiology and pathogenesis of 
HNSCC and the use of radiation treatment and functional 
surgery for this disease, survival rates have not improved 
over the past 40 years [4].
The Hippo pathway is a major tumor-suppressor 
pathway in many cancers and, in general, has important 
regulatory functions in cell proliferation, cell survival, cell 
competition, and maintenance of a stem cell phenotype 
[5]. The Hippo pathway consists of a regulatory serine-
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threonine kinase module and a transcriptional module. The 
kinase module includes mammalian STE20-like protein 
kinase 1 (MST1) and MST2, large tumor suppressor 1 
(LATS1) and LATS2, together with the adaptor proteins 
Salvador homologue 1 (SAV1), MOB kinase activator 
1A (MOB1A), and MOB1B [6-11]. These inhibitory 
kinase modules regulate tissue growth by suppressing the 
transcription module such as the Yes-associated protein-1 
(YAP1) and transcriptional co-activator with PDZ-binding 
motif (TAZ) [12]. YAP1 is a key conduit for Hippo 
pathway regulation and output [5]. Hyperactivation of 
YAP1 is widespread in cancers. Previous studies showed 
that cancer features such as cancer stem cell properties, 
epithelial-mesenchymal transition (EMT), increased 
migration, and metastasis are regulated by YAP1 [11]. In 
a study of the mutational landscape across 12 major cancer 
types, significantly mutated genes of hippo signaling were 
found in several cancers included HNSCC [13].
In oral squamous cell carcinoma, nuclear YAP1 
accumulation marked premalignant dysplastic regions 
of the oral epithelium and YAP1 promoted tumorigenic 
phenotypes and a transcriptional program associated with 
tumor progression [14]. YAP1 expression in combination 
with p63 can facilitate identification of HNSCC tumors 
from hyperplastic and benign tissues [15]. Furthermore, 
YAP1 upregulation is known to be related with resistance 
to anticancer drugs such as docetaxel, cisplatin, and 
cetuximab in several cancers [16-18]. In oral squamous 
cell carcinoma cell lines, nuclear translocation of YAP1 
correlated with the acquisition of cisplatin resistance [19]. 
In HNSCC, amplification of the YAP1 gene was linked 
to cetuximab resistance in cell lines [20]. However, the 
clinical relevance of YAP1 activation has still not been 
examined in HNSCC.
In the current study, we systematically characterized 
the genomic data from multiple cohorts of patients with 
HNSCC and found a molecular subtype characterized by 
YAP1 activation and poor prognosis. We analyzed the gene 
alterations associated with YAP1 using multiplatforms. We 
further showed that YAP1 may play roles in resistant to 
immunotherapy.
RESULTS
Activation of YAP1 in HNSCC
Although activation of YAP1 has been reported in 
many cancers [5, 16, 18, 21-24], its relative activity across 
all cancer types has not been systematically examined. 
Because amplification is one common activation 
mechanism of YAP1 [25, 26], we first examined copy 
number alteration of YAP1 in 26 cancers by using genome 
copy number data from TCGA. HNSCC is the second 
most common YAP1-amplified cancer type (8.6%) after 
cervical cancer (12.6%) (Supplementary Figure 1A), 
suggesting that YAP1 activation might be a critical genetic 
event for development of HNSCC. Expression of YAP1 
was significantly correlated with copy number alteration 
(Figure 1A, r = 0.781, P < 0.001), further supporting 
functional roles of YAP1 in the development of HNSCC. 
Interestingly, expression of YAP1 was substantially higher 
in many tumors without YAP1 amplification, suggesting 
that copy number alteration is not the only mechanism of 
YAP1 activation in HNSCC (Figure 1A).
Because the best-known molecular activity of 
YAP1 is transcription activation, we sought to identify 
potential downstream targets of YAP1 by finding genes 
with expression significantly correlated with copy 
number alterations (P < 0.001 and Pearson correlation 
coefficient > 0.2 or < –0.2), yielding 652 genes (copy 
number-associated genes). We next constructed a 
prediction model with these potential downstream target 
genes to estimate YAP1 activity in HNSCC by using the 
BCCP model. Briefly, tumors were first divided into two 
groups according to copy number alterations: YAP1-high 
(GISTIC score >2) and YAP1-low (GISTIC score <2). 
As expectedly, the vast majority of YAP1-high tumors 
showed a high probability (>0.5) of YAP1 activity when 
BCCP was applied to gene expression data. Interestingly, 
many tumors without YAP1 amplification also showed 
a high probability of YAP1 activity (Figure 1A), further 
supporting our notion that YAP1 amplification may not 
be the only mechanism for YAP1 activation in HNSCC. 
Because many tumors showed high YAP1 expression 
without YAP1 amplification, we also identified genes with 
expression significantly correlated with mRNA expression 
of YAP1 (P < 0.001 and Pearson correlation coefficient > 
0.2 or < –0.2). This search yielded 4552 genes (mRNA-
associated genes). To identify key downstream targets 
of YAP1 in HNSCC, we further selected 292 genes that 
were shared in both gene lists (Supplementary Figure 1B, 
Supplementary Table 1). To assess the clinical relevance 
of YAP1 activation in HNSCC, patients were re-stratified 
according to BCCP probability: YAP1-active (YA >0.5) 
and YAP1-inactive (YI <0.5) (Figure 1B). Overall 
survival (OS) time of patients with the YA subtype was 
significantly worse than that of patients with the YI 
subtype, suggesting that YAP1 activation is significantly 
associated with poor prognosis in HNSCC (Figure 1C).
YAP1 signature was associated with the 
prognosis of HNSCC
Having shown that gene expression signature 
accurately reflecting activation of YAP1 and had a 
significant association with prognosis, we next sought to 
validate its association in the independent cohorts (Leipzig, 
Greek, MD Anderson, and Seattle cohorts) (Figure 2A). 
Patients in these cohorts were stratified to the YA or YI 
group by BCCP classifier (Supplementary Figure 2, Table 
1). When this stratification was applied to the Leipzig 
cohort, 115 (42.6%) of 270 patients were classified as YA 
Oncotarget111132www.impactjournals.com/oncotarget
(Table 1), and their prognosis was significantly worse than 
for patients in the YI group (OS 27.7% vs. 38.3% at 5 years, 
P = 0.021) (Figure 2B). Of 109 patients in the Greek cohort, 
30 (27.5%) were classified as YA, and the patients with the 
YA subtype had a significantly worse disease-free survival 
than did patients with the YI subtype (37.8% vs. 65.1% at 5 
years, P = 0.008) (Figure 2B). In the MD Anderson cohort, 
19 (25.7%) of 74 patients were classified as YA and had 
significantly worse disease-free survival than those with 
the YI subtype (43.3% vs. 75.8%, P = 0.008) (Figure 2B). 
Consistent with previous observation, patients classified 
as YA subtype in the Seattle cohort (35 patients or 36.1%) 
also showed significantly poorer prognosis (P = 0.019) 
(Figure 2B).
We next performed analyses to determine whether 
the prognostic effect of the YAP1 signature was 
independent of other clinical variables. Three cohorts 
(TCGA, Leipzig, and MD Anderson) with available OS 
data were pooled for a Cox proportional hazards model 
(n = 808). In univariate analysis, YAP1 signature (YA 
group vs. YI group), sex, age (<60 years old vs. ≥60 years 
old), anatomic site (oropharynx vs. non-oropharynx), and 
primary tumor (T4 vs. non-T4) were significant prognostic 
factors (Table 2). To address a potential confounding 
effect, we performed a multivariate risk analysis using the 
Cox proportional hazards model and found that the YAP1 
signature was the most significant predictor of OS (hazard 
ratio 1.31, 95% confidence interval 1.03-1.67, P = 0.028).
Figure 1: Activation of YAP1 in HNSCC. (A) Scatter plots between mRNA expression and copy number alteration of YAP1 in TCGA 
cohort. The expression of YAP1 was substantially higher in many tumors without YAP1 amplification (in circle). (B) Expression patterns of 
292 genes in the YAP1 signature. The data are presented in matrix format, in which each row represents an individual gene and each column 
represents a tissue specimen. Each cell in the matrix represents the level of expression of a gene feature in an individual sample. The red 
and green cells reflect relatively high and low expression levels, respectively. YA, YAP1 activated; YI, YAP1 inactivated. (C) Kaplan-Meier 
plots of the YA and YI patients in TCGA cohort. Overall survival time of patients with the YA subtype was significantly worse than that of 
patients with the YI subtype. P values were calculated using log-rank tests. +, censored data.
Oncotarget111133www.impactjournals.com/oncotarget
Next, we assessed whether YAP1 activation may 
have a potential association with the patient’s response 
to radiation therapy. We pooled the patient data from 
TCGA and MD Anderson cohorts with available radiation 
data (n = 458). For the patients who underwent radiation 
therapy, the survival of patients with the YA subtype was 
significantly worse than for patients with the YI subtype 
(P = 0.03) (Supplementary Figure 3A). For the YA group, 
radiation therapy did not improve the survival rate 
(P = 0.15) (Supplementary Figure 3B). However, radiation 
therapy improved the survival rate of the YI group (P = 
0.04) (Supplementary Figure 3C), suggesting that YAP1 
activation might be associated with radioresistance in 
HNSCC.
Copy number alteration associated with YAP1 
activation
To further examine the genomic properties 
associated with YAP1 activation, we compared the 
copy number alteration between the YA and YI groups 
(Figure 3). Somatic copy numbers were obtained for 
513 samples in TCGA cohort. When frequency of 
significantly reoccurring alterations was compared using 
Fisher’s exact test, the YA group had amplification of 
7p11.2 (EGFR) and 8q11.21 (SNAI2). The YA group 
had deletion of 8p23 (CSMD1), 9p21.3 (CDKN2A), 
9q34.3 (NOTCH1), and 18q21.2 (SMAD4). CSMD1, 
CDKN2A, NOTCH1, and SMAD4 are known to be 
Figure 2: Construction of a prediction model using YAP1 gene signature and clinical significance of YAP1 activation 
in HNSCC. (A) Schematic diagram of the strategy used to construct the prediction model and evaluate predicted HNSCC outcomes 
according to the gene expression signature. (B) Kaplan-Meier plots of the YA and YI patients in four independent test cohorts. P values were 
calculated using log-rank tests. +, censored data.
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Table 1: Patient’s characteristics in 5 cohort
TCGA cohort Leipzig 
cohort
Greece cohort MDACC cohort Seattle cohort
Number of patients 513 270 109 74 97
Gender
 Male 370 (73.7%) 223 (82.6%) 104 (95.4%) 58 (78.4%) 66 (68.0%)
 Female 132 (26.3%) 47 (17.4%) 5 (4.6%) 16 (21.6%) 31 (32.0%)
Age (mean ± SD) 60.9 ± 11.9 60.1 ± 10.0 63.3 ± 10.1 58.1 ± 13.6 NA
Anatomic site
 Oral cavity 301 (60.0%) 83 (30.7%) 0 71 (95.9%) 86 (88.7%)
 Oropharynx 79 (15.7%) 102 (37.8%) 0 3 (4.1%) 11 (11.3%)
 Larynx 113 (22.5%) 48 (17.8%) 109 (100%) 0 0
 Hypopharynx 9 (1.8%) 33 (12.2%) 0 0 0
 others 0 4 (1.5%) 0 0 0
Primary tumor
 T1 33 (6.8%) 35 (13.0%) NA 3 (4.1%) NA
 T2 147 (30.2%) 80 (29.6%) NA 27 (36.5%) NA
 T3 129 (26.5%) 58 (21.5%) NA 28 (37.8%) NA
 T4 178 (36.6%) 97 (35.9%) NA 16 (21.6%) NA
Regional lymph node
 N0 238 (49.5%) 94 (34.8%) 42 (56.8%) NA NA
 N1 79 (16.4%) 32 (11.9%) 13 (17.6%) NA NA
 N2 155 (32.2%) 132 (48.9%) 19 (25.7%) NA NA
 N3 9 (1.9%) 12 (4.4%) 0 NA NA
Stage
 I 20 (4.1%) 18 (6.7%) 12 (11.0%) 3 (4.1%) 30 (30.9%)
 II 96 (19.6%) 37 (13.7%) 18 (16.5%) 16 (21.6%) 11 (11.3%)
 III 101 (20.7%) 37 (13.7%) 36 (33.0%) 15 (20.3%) 15 (15.5%)
 IV 272 (55.6%) 178 (65.9%) 43 (39.4%) 40 (54.1%) 41 (42.3%)
HPV status
 Positive 68 (19.9%) 60 (23.4%) NA NA 0
 Negative 274 (80.1%) 196 (76.6%) NA NA 97 (100%)
Tobacco use
 Never 114 (23.3%) 48 (17.8%) 1 (0.9%) 15 (20.3%) NA
 Yes 376 (76.7%) 222 (82.2%) 108 (99.1%) 59 (79.7%) NA
Alcohol use
 Never 154 (42.1%) 31 (11.5%) 51 (46.8%) NA NA
 Yes 212 (57.9%) 239 (88.5%) 58 (53.2%) NA NA
YAP1 signature
 YAHSC 187 (36.5%) 115 (42.6%) 30 (27.5%) 19 (25.7%) 35 (36.1%)
 YIHSC 326 (63.5%) 155 (57.4%) 79 (72.5%) 55 (74.3%) 62 (63.9%)
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Table 2: Univariate and multivariate Cox Proportinal Hazard Regression Analyses of variables affecting 5-year 
overall survival rate (patients data: TCGA cohort, Leipzig cohort, MDACC cohort; n=808)
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
YAP1 signature (YAP1 activated) 1.41 (1.12-1.77) 0.004 1.31 (1.03-1.67) 0.028
Gender (male) 0.77 (0.60-1.0) 0.05 0.85 (0.65-1.12) 0.247
Age (≥ 60 y) 1.30 (1.04-1.64) 0.024 1.26 (0.99-1.61) 0.066
Anatomic site (oropharynx) 0.54 (0.32-0.92) 0.025 0.63 (0.37-1.10) 0.104
Primary tumor (T4) 2.03 (1.00-4.12) 0.049 1.81 (0.88-3.73) 0.108
Regional lymph node (N+) 1.02 (0.81-1.28) 0.9 1.01 (0.76-1.34) 0.971
Stage (stage III & IV) 1.21 (0.91-1.62) 0.19 1.08 (0.74-1.56) 0.695
Figure 3: DNA copy number alterations in TCGA HNSCC cohort. (A) Heat map of copy number alterations of tumors stratified 
by YAP1 subtype. (B) Copy number gains and losses in YA and YI subtypes. For each gene, the mean of the segmented GISTIC copy 
number values, in YA and YI subtypes were computed and plotted in genomic order.
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tumor-suppressor genes. The YI group was distinguished 
by amplification of 3q26/28 (PIK3CA, SOX2, and TP63) 
and deletion of 11q23.1 (Supplementary Table 2). Gains 
in the 3q, 5p, and 8q chromosomal regions were features 
of HNSCC and lung squamous cell carcinoma [27]. 
Interestingly, while gain in the 3q region was higher in 
the YI group, gain in the 8q region was higher for the 
YA group. There was no difference in 5p between the 
two groups.
Somatic mutation associated with YAP1 
activation
To assess co-occurring somatic mutations with 
YAP1 activation in HNSCC, we also analyzed somatic 
mutation data in TCGA cohort (n = 493). When 30 
significantly mutated genes in HNSCC were analyzed for 
association with YAP1 activation [13, 27], TP53 (82.6% 
vs. 64.4%, P = 1.4 × 10-5) and CDKN2A (28.3% vs. 
19.1%, P = 0.02) were identified as co-occurring mutated 
genes (Figure 4, Supplementary Table 3). The mutations of 
NFE2L2 (1.1% vs. 7.8%, P = 7.0 × 10-4), PTEN (0.5% vs. 
4.2%, P = 0.022), SYNE1 (14.1% vs. 22.3%, P = 0.025), 
and NSD1 (8.2% vs. 14.9%, P = 0.033) were mutually 
exclusive for YAP1 activation. Interestingly, AJUBA has 
been implicated in the Hippo pathway and was segregated 
predominantly in HPV-negative tumors [27]. However, 
AJUBA did not significantly differ between groups (7.1% 
vs. 5.8%, P = 0.57).
miRNAs associated with YAP1 activation
To explore potential interactions between YAP1 
activation and miRNAs in HNSCC, we analyzed 
miRNA expression data from TCGA cohort (n = 473 
tumors). Expression of 12 miRNAs was significantly 
associated with YAP1 activation (fold change >2, P < 
0.001) (Figure 5A, Supplementary Table 4). miRNA-1-2, 
miRNA-133a, miRNA-133b, and miRNA-206 are known 
to be frequently downregulated in cancer [22]. They are 
also known to be involved in the regulation of molecular 
networks such as Wnt signaling pathway, tight junction, 
and MAPK signaling pathway in cancer [22]. Because 
these miRNAs were significantly upregulated in the YA 
subtype, they might be regulated through YAP1-associated 
signaling pathways.
Because many tumors in the YA subtype had 
high expression of YAP1 without YAP1 amplification 
(Figure 1A), we hypothesized that certain miRNAs 
might play roles in the regulation of YAP1 in these 
tumors [copy number-independent (CNI)-YA]. Thus, we 
sought to find miRNAs whose expression is specifically 
higher in CNI-YA than in copy number-dependent 
(CND) YA, YI, or normal head and neck tissues. We 
first selected miRNAs whose expression significantly 
differed between CNI-YA and CND-YA (fold ratio 
>1.5, P < 0.01) and further selected miRNAs whose 
expression was significantly different between CNI-YA 
and normal head and neck tissues (P < 0.05), yielding 21 
Figure 4: Somatic mutation in HNSCC according to two subgroups. The mutations of TP53 and CDKN2A were identified as 
co-occurring mutated genes in YA subgroup. The mutations of NFE2L2, PTEN, SYNE1, and NSD1 were mutually exclusive for YAP1 
activation.
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miRNAs (Supplementary Table 5). Of these miRNAs, 
only expressions of miRNA-187 and miRNA-675 were 
significantly higher in CNI-YA than in YI or in normal 
tissues (Supplementary Figure 4). In good agreement with 
our hypothesis, many of the predicted target genes of both 
miRNAs are negative upstream regulators of YAP1 in the 
Hippo pathway (Supplementary Table 6, Supplementary 
Figure 5), suggesting that YAP1 in CNI-YA tumors might 
be activated through miRNA-mediated mechanisms.
Clinical characteristics associated with YAP1 
activation
We next assessed the association of the two 
subtypes with clinical characteristics of HNSCC in 
TCGA cohort. Among clinically recognized features such 
as lymph-node metastasis and T stages, YAP1 activation 
was significantly associated with HPV status (P = 4.29 × 
10-7, Figure 5B). In TCGA cohort, HPV status data were 
available from only 279 of the 513 patients. Of 36 HPV-
positive patients, most (n = 35) were in the YI subgroup. 
We also assessed the association of YAP1 activation 
with four previously recognized molecular subtypes of 
HNSCC (Supplementary Table 7) [28]. YAP1 activation 
was most associated with the basal subtype, as reflected 
in the fact that the highest proportion of patients (58.7%) 
in the YA subtype was from the basal subtype (P = 2.2 × 
10-6, Figure 5B). TheYI subgroup lacked any significant 
association with the four subtypes as it was found in 
similar proportions in the four subtypes: atypical subtype 
(33.3%), classical subtype (24.9%), mesenchymal 
subtype (22.0%), and basal subtype (19.7%).
Figure 5: Molecular characteristics of the YA and YI subtypes. (A) miRNAs that are differentially expressed in the YA and 
YI subtypes. (B) Association between YAP1 signature and the other subtypes of HNSCC. HPV infection status was most significantly 
associated with the two subtypes. Of 105 YA patients, 104 were HPV-negative (P = 4.29 × 10-7).
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Association of YAP1 activity with host immune 
activity
Recent clinical trial demonstrated clinically 
meaningful anti-tumor activity of pembrolizumab, 
humanized antibody against immune checkpoint inhibitor 
PD-1, in HNSCC [29]. Since study also showed that 
composite scores from expression of 6 interferon γ 
(INFG)-related genes (CXCL9, CXCL10, IDO1, IFNG, 
HLA-DRA, and STAT1) were good predictor for 
identifying responders of pembrolizumab treatment, we 
next assessed association of two subtypes with potential 
response to permbrolizumab treatment by generating 
INFG composite scores in TCGA cohort. Interestingly, 
YA subtype has significantly low INFG composite scores 
(P =8.1 x 10-5) (Figure 6A), suggesting that YAP1 may 
suppress immune activity related immune checkpoint 
regulation. Further support of the idea is supplied by 
significant negative correlation between IFNG composite 
scores and Bayesian probability of active YAP1 in 
TCGA cohort (Figure 6B). Consistent with results from 
TCGA cohort, IFNG scores were significantly lower in 
YA subtype (P = 0.001) and negatively correlated with 
Bayesian probability of active YAP1 in Leipzig cohort 
(Figure 6C and 6D).
DISCUSSION
By systematically analyzing genomic copy number 
data and mRNA expression data of YAP1 in HNSCC, we 
identified a gene expression signature reflecting YAP1 
activation (YAP1 signature) that is significantly associated 
with the prognosis of patients with HNSCC. Robustness 
of the signature was validated in five independent 
cohorts of patients with HNSCC, as patients with the YA 
subtype had worse survival rates than patients with the 
YI subtype in all examined cohorts. The YAP1 signature 
was an independent prognostic factor. In multiplatform 
analysis, YA patients had gain of EGFR and SNAI2; loss 
of tumor-suppressor genes such as CSMD1, CDKN2A, 
NOTCH1, and SMAD4; and high mutation rates of TP53 
and CDKN2A. YI patients were characterized by gain 
of PIK3CA, SOX2, and TP63; deletion of 11q23.1; and 
high mutation rates of NFE2L2, PTEN, SYNE1, and 
NSD1. To our knowledge, we are the first to report the 
clinical significance of YAP1 activation in HNSCC and 
demonstrate that the YAP1 signature can be used as a 
prognostic biomarker for HNSCC.
Our study results are in good agreement with 
previous observations in other cancers [18, 30-34]. 
Activation of YAP1 has been correlated with poor 
prognosis for colorectal cancer and poor response to 
cetuximab [18]. Likewise, activation of YAP1 was 
significantly associated with poor prognosis in ovarian 
cancer, liver cancer, and gastric cancers [18, 32-34]. 
Previous studies showed that YAP1 had a role in the 
onset, progression, and drug resistance in HNSCC [14, 
15, 19, 20]. Hiemer et al. reported that YAP1 and TAZ 
activity drives oral squamous cell carcinoma proliferation, 
survival, and migration in vitro and vivo [14]. YAP 
expression was elevated in tumor compared with benign 
tissues and was associated with nodal metastasis [15]. A 
potential association of YAP1 with resistance to radiation 
therapy was also supported by previous studies, as 
amplification of YAP1 was correlated with cetuximab 
sensitivity in HNSCC [20] and knockdown of YAP1 
increased the sensitivity to cisplatin in vitro [19].
Comparisons of copy number alteration and somatic 
mutation showed significant differences between the two 
subtypes. The YA group had more loss of copy number and 
a higher somatic mutation rate of the cell cycle–related 
gene CDKN2A. In good agreement with a previous study 
demonstrating that deletion of CDKN2A and inactivating 
mutation were associated with HPV-negative tumors [27], 
the vast majority of tumors with the YA subtype were 
HPV-negative tumors, suggesting that YAP1 activation 
and inactivation of CDKN2A might be associated genetic 
events. Thus, it will be interesting to determine in future 
investigations whether YAP1 can downregulate CDKN2A. 
Tumors of the YA subtype were also characterized by gain 
of EGFR and SNAI2. SNAI2 has five zinc finger domains 
that play a pivotal role during embryo development and 
mesenchymal tumorigenesis and has been found to be 
overexpressed in several cancers, and it also promotes 
invasion in lung adenocarcinoma, glioma, and ovarian, 
cervical, and pancreatic cancers and is a prognostic 
marker in some cancers [24, 35]. The YA subtype was 
also characterized by a higher mutation rate of the tumor-
suppressor gene associated with cell survival (TP53) and 
loss of copy number of tumor-suppressor genes (CSMD1, 
NOTCH1, and SMAD4), while the YI subtype was 
characterized by high mutation rates of NFE2L2, PTEN, 
SYNE1, and NSD1. Spectrin repeat containing nuclear 
envelope protein 1 (SYNE1) gene has been implicated in 
the regulation of nuclear polarity, a process that operates 
upstream of NOTCH1 in squamous epithelia [35]. 
SYNE1 mutation was associated with autosomal recessive 
cerebellar ataxia [24] and is known to be associated with 
glioblastoma and lung, ovarian, colorectal, and head and 
neck cancers [35, 36]. The nuclear receptor binding SET 
domain protein 1 (NSD1), a histone methyltransferase, 
was found to be frequently mutated in the clear cell 
variant of renal cell carcinoma and associated with DNA 
hypomethylation [27].
In assessing the association of the YAP1 subgroup 
with the four previously discovered molecular subtypes 
[28], we found that the YA group had the most 
similarity with the basal subtype. The basal subtype 
was characterized by inactivation of NOTCH1 and 
co-amplified 11q13/q22 (21) in which YAP1 resided. 
Interestingly, 94.5% of atypical subtype was YI subtype 
(Supplementary Table 7). The atypical subtype was 
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characterized by enrichment of HPV-positive tumor and 
activating mutations in exon 9 that contain PIK3CA (21). 
In good agreement with this, the YI subtype included most 
of the HPV-positive tumors and featured the amplification 
of copy number of PIK3CA. While the YAP1-associated 
subtype shares some molecular features with the four 
previously recognized molecular subtypes, it is important 
to point out that this subtype is clinically relevant as 
reflected in prognostic difference and response to radiation 
therapy, while clinical association of the four molecular 
subtypes has not been clearly demonstrated yet [28].
Recent advances in our understanding of 
onco-immunology has led to the development of 
immunotherapies. Particularly, a blockade of checkpoint 
molecules such as CTLA-4 and PD-1 has emerged as a 
novel therapeutic approach in oncology [37-39]. PD-1 is 
a negative co-stimulatory receptor and a strong inhibitor 
of T cell response [40]. Pembrolizumab targeting PD-1 
has been approved for the treatment of multiple cancers 
including metastatic melanoma [41]. Six-gene based IFNG 
composite scores were developed and tested as predictor 
for response to pembrolizumab treatment in HNSCC [29]. 
When immune activity reflecting potential response to 
pembrolizumab in HNSCC tumors was assessed by using 
IFNG scores, tumors in YA subtype have lower scores and 
IFNG scores were negatively correlated with YAP1 activity, 
suggesting that YAP1 may be involved in regulation of host 
immunity against cancer cells. Thus, YA subtype might 
Figure 6: Negative association of YAP1 activity with IFNG scores in HNSCC (A, C). Comparison of the IFNG scores between 
YA subgroup and YI subgroup in TCGA and Leipzig cohort. (B, D) Scatter plots between IFNG scores and Bayesian probability of YAP1 
activity is TCGA and Leipzig cohort.
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be more resistant to immunotherapy. Since YA subtype is 
poor prognostic, it would be also interested to see if YAP1-
mediated low immune activity contributes to aggressiveness 
of cancer cells in YA subtype in future study.
This study has some limitations. First, all cohorts 
examined in our study were retrospective cohorts. Second, 
while patients in the YI subgroup showed better survival than 
those in the YA subgroup when treated with radiation therapy, 
an interaction test failed to show significant interaction 
between subgroups and radiation therapy. Thus, these 
observations should be validated in future prospective study.
In conclusion, our newly discovered clinically 
relevant subgroup may help facilitate rational design of 
clinical studies by stratifying patients according to their 
prognostic risk and response to therapy. Prospective 
studies are needed to validate the clinical usefulness of 
the two subgroups.
MATERIALS AND METHODS
Patients and gene expression data
This study used patient data from five independent 
sources. Gene expression, mutation, miRNA, and copy 
number data of The Cancer Genome Atlas (TCGA) cohort 
were downloaded from the UCSC Cancer Genomics 
Browser (https://genome-cancer.ucsc.edu/) [27]. mRNA 
expression, miRNA expression, copy number alteration, 
and mutation data were available from 513, 473, 513, 
and 493 patients respectively. We also used the gene 
expression and clinical data for four independent cohorts 
available from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo). These four 
cohorts consisted of data from the Institute for Medical 
Informatics, Statistics and Epidemiology (Leipzig 
cohort, GSE65858, n = 270) [42], Aristotle University of 
Thessaloniki (Greek cohort, GSE27020, n = 109) [43], 
MD Anderson Cancer Center (MD Anderson cohort, 
GSE42743, n = 74) [44], and Fred Hutchinson Cancer 
Research Center (Seattle cohort, GSE41613, n = 97) [44]. 
Table 1 shows the pathologic and clinical characteristics 
of the patients in all five cohorts.
Statistical analysis
The BRB-ArrayTools software program (http://brb.
nci.nih.gov/BRB-ArrayTools/) was used for analysis of 
gene expression data [45]. The R language environment 
(http://www.r-project.org) was used for other statistical 
analyses. Raw data on the patient cohorts were normalized 
using a robust multiarray averaging method [46]. A 
stringent threshold was used to minimize the number 
of false-positive findings. Pearson correlation was used 
for correlation analysis. We estimated prognoses using 
Kaplan-Meier plots and the log-rank test. We used 
univariate and multivariate Cox proportional hazards 
regression analyses to evaluate independent prognostic 
factors associated with survival. Independent t-test was 
used to compare values between two groups. Fisher’s 
exact test was used to evaluate the frequency difference 
of copy number alteration and somatic mutation. P values 
less than 0.05 indicated statistical significance, and all 
statistical tests were two-tailed. A heatmap was generated 
using the Cluster and TreeView software programs 
[47]. Target genes of miRNAs were predicted by using 
miRWalk 2.0 (http://zmf.umm.uni-heidelberg.de/) [48].
Gene expression data and construction of the 
prediction model
Gene expression data of TCGA cohort were 
sequenced by Illumina HiSeq2000, the Leipzig cohort 
by Illumina HumanHT-12 V4.0 expression beadchip, 
the Greek cohort by Affymetrix Human Genome U133A 
Array, and the MD Anderson and Seattle cohorts by 
Affymetrix Human Genome U133 Plus 2.0 Array. All 
gene expression data were standardized independently 
across all samples before they were integrated and 
analyzed together. The strategy used to develop and 
validate the prediction model on the basis of the gene 
expression signature and to estimate predictive accuracy 
was adopted from previous studies [49-51]. To find YAP1-
specific genes in HNSCC, we applied a double correlation 
approach to gene expression data from TCGA cohort. 
We first identified YAP1-associated genes by using the 
correlation between copy number of YAP1 and mRNA 
expression of each gene (copy number-associated genes). 
Likewise, we also identified second YAP1-associated 
genes by using the correlation between mRNA expression 
of YAP1 and mRNA expression of each gene (mRNA-
associated genes). Genes were selected if the P value 
was less than 0.001 and the correlation coefficient was 
more than 0.2 or less than –0.2. Expression patterns of 
292 shared genes in two YAP1-associated gene lists were 
considered as the YAP1 signature in HNSCC and used 
for construction of the prediction model. We used data 
from TCGA cohort as the training set and data from the 
Leipzig, Greek, MD Anderson, and Seattle cohorts as test 
sets. The expression patterns of the 292 genes from TCGA 
cohort were combined to form a classifier according to 
a Bayesian compound covariate (BCCP) predictor [52]. 
The robustness of the classifier was estimated using a 
misclassification rate determined during leave-one-out 
cross-validation in the training set. The BCCP classifier 
estimated the likelihood that an individual patient had 
either a YAP1-active subtype or YAP1-inactive subtype.
Copy number analysis
We used the HNSCC copy number data (gistic2) in 
Cancer Browser (https://genome-cancer.ucsc.edu). Threshold 
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copy number at reoccurring alteration peaks from GISTIC 
analysis of BRB CGH-Tools was used for comparison of 
focal peak frequency across subgroups by YAP1 signature. 
Fisher’s exact test was used for frequency comparisons of 
significantly reoccurring alterations by YAP1 signature. For 
comparison of amplification, only high-level events were 
considered (gistic ≥2), and for deletion all events were used 
as described in a previous study (21).
Association with YAP1 signature and other 
subtypes of HNSCC
For assessing the association with previously 
published molecular classifications of HNSCC [28], 
we evaluated four previously established molecular 
classifications: atypical, classical, basal, and 
mesenchymal. The predictor was adjusted from 790 genes. 
Each sample was assigned an expression subtype using the 
BCCP predictor.
Association with YAP1 signature and interferon 
interferon γ signature
A six-gene signature of interferon γ-related genes 
(CXCL9, CXCL10, IDO1, IFNG, HLA-DRA, and 
STAT1) was used in TCGA cohort. The interferon γ score 
was calculated as the average of the value of the six genes. 
The interferon γ score was compared with t-test between 
YA group and YI group.
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